



**WCIO  
2016**

BOSTON, MA | 9-12 JUNE

SEAPORT BOSTON HOTEL & WORLD TRADE CENTER

# ***Percutaneous Radiofrequency Ablation for Metastatic Spinal Disease: An Innovative Minimally Invasive Technique by Using a Navigational Spine Tumor Ablation System***

## **Claudio Pusceddu**



***Dpt of Interventional Radiology  
Oncological Hospital  
AOB - Cagliari - ITALY***



- 
- **No disclosures**

# Focal Palliative Treatment of Bone Metastases

- **Radiation Therapy:**

- **EBRT:** Standard of Care for bone met palliation

- *Rate and degree of pain relief,*
- *Requires interruption of chemotherapy and multiple fractions*
- *Maximum tolerable dose limitations*

- **SBRT:**


- *Faster and more efficient pain relief*
- *Immobilization of painful patients for planning and treatment*
- *Associated with increased risk of fracture Boehling et al (20%) ; Rose et al (40%)*

- **Surgical intervention**

- *Neurologic deficit instability requiring decompression, stabilization, corpectomy*
- *Invasive, risk/benefit*

- **Minimally Invasive Ablative Therapy**

- *Acute pain relief*
- *Complimentary to Conventional Radiotherapy*
- *Access, Navigation has limited adoption*







# Objectives:



Retrospectively evaluate feasibility, safety and effectiveness of radiofrequency ablation (RFA) using the **Spinal Tumor Ablation (STAR) System** in palliative treatment of painful vertebral metastases.

# Access and Navigation has limited adoption in the treatment of spinal metastases.

F/49 single mts L1 from breast cancer












## Spinal Tumor Ablation (STAR) System

Result after combined  
RFA and Vertebroplasty



# STAR system



Power Level 1 (5 Watts)



# Methods and Materials


➤ **16** Patients treated:  
(mean age 56 yr (36-81))

➤ **19** vertebral metastases

**12** thoracic

**7** lumbar

Site of the treatment



Average Pain was **6.7** (VAS from 4.1 to 8.2)


**14 of 16** patients underwent PMMA augmentation

**Median F.U. 10 months (3-13).**



# Case 1



39 Year old patient with spinal metastases after Breast Cancer  
Pain, functional disability VAS 7 (0 – 10)



T8



May 2014





# May 2014 (RT)



11 months

13 months

8 months




# Case 2 45 Year old patient with a single spinal metastasis after Breast Cancer - VAS 7




**Radiotherapy  
before RFA**






# Persistent pain! Vas 4



**STAR**






**Vas 0**  
**Complete lack of C.E.**




# Case 3

55 Year old patient with a single spinal metastasis after Breast Cancer - VAS 5






# Before ablation



# After ablation



DOB: 11/12/1961  
Study Date: 13/04/2016

Study Name: PET\_02\_PETCT\_WholeBody (Adult)



# Results

- Technical Success 100%
- Complications (none)
- **Pain relief** (before; 1 week and 6 months after)

**VAS** decreases from 6.7 (range 4.1 – 8.2)  
to 1.3 (range 0 to 2.8)

**No local relapse**

**No tumor progression** in the treated site

Median F.U. 10 months (3-13 months)



# Conclusions

- Use of a navigational RFA device to treat metastatic spinal lesions is a safe and effective procedure which allowed reduction of local tumor burden with significant pain relief and good local control of the metastasis.
- Targeted RFA seems to be a promising alternative for patients who are not candidates for surgery.



*Thanks*



**Claudio Pusceddu**



*clapusceddu@gmail.com*

*www.radiologia-interventistica-oncologica.it*